The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for game-changing treatments and substantial returns is undeniable, the associated risks are also notab